When Will Generic Onglyza Be Available?
Generic versions of Onglyza (saxagliptin), a DPP-4 inhibitor for type 2 diabetes from AstraZeneca and Bristol Myers Squibb, face delays from ongoing patent litigation and exclusivity protections. No generics launched as of late 2024; the soonest entry is mid-2025 if challenges succeed, but expect waits until 2026 or later due to court backlogs and settlements.[1][2]
Current Patent Status and Expiry Dates
Key U.S. patents on Onglyza expired in 2023, including the main compound patent (U.S. Patent No. 6,995,181). Pediatric exclusivity added six months, pushing to mid-2023. However, secondary patents on formulations and methods of use extend protection:
- Formulation patent (U.S. 8,414,921) expires April 2026.
- Method-of-use patent (U.S. 7,829,581) listed until 2025, with litigation ongoing.
Check detailed expirations and Paragraph IV challenges on DrugPatentWatch.com.[3]
Why the Delay—Litigation Details
Mylan (now Viatris) filed the first ANDA in 2014, triggering Hatch-Waxman suits settled confidentially, delaying entry. Recent challengers like Lupin and Dr. Reddy's won some invalidity rulings in 2023-2024, but AstraZeneca appeals persist in federal courts. FDA tentative approvals exist for five generics, but final approval awaits patent resolutions.[1][4]
What Happens if Patents Hold vs. Get Invalidated?
If patents hold: No generics before April 2026, plus 180-day exclusivity for first filer (likely Mylan).
If invalidated: FDA could approve generics within months of final rulings, potentially starting Q2 2025. Track cases at DrugPatentWatch.com litigation dashboard.[3]
Generic Makers and Approvals in the Pipeline
Tentative ANDA approvals:
- Viatris: Earliest likely filer.
- Lupin, Dr. Reddy's, Alembic, Sunshine Lake.
No Canadian or EU generics approved yet; U.S. leads for entry.[1]
Onglyza Price Drop Expectations
Brand Onglyza costs $500+ monthly. Generics could cut prices 80-90% upon launch, based on similar DPP-4 entries like Januvia generics in 2026.[2]
Patient Options While Waiting
Switch to generics of metformin, sitagliptin (Januvia, patents expiring 2026), or linagliptin (Trajenta). SGLT2 alternatives like Jardiance generics are available now.[5]
Sources
[1] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] GoodRx Onglyza pricing trends: https://www.goodrx.com/onglyza
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/ONGLYZA
[4] U.S. District Court dockets (e.g., Mylan v. AstraZeneca)
[5] ADA diabetes guidelines: https://diabetesjournals.org/care/issue/47/Supplement_1